In cancer cells, Akt inhibits the activation of the Raf-MEK-ERK pathway [36] and mTORC1 inhibition results in hyperactive RTK/IRS-1/PI3K pathway increasing the signal towards both, the mTORC2 and the Ras-Raf1-MEK1/2-ERK pathway [37]. The gene discussed is MAP2K1; the disease is cancer.